1. Academic Validation
  2. Neuroprotective properties of mildronate, a mitochondria-targeted small molecule

Neuroprotective properties of mildronate, a mitochondria-targeted small molecule

  • Neurosci Lett. 2010 Feb 12;470(2):100-5. doi: 10.1016/j.neulet.2009.12.055.
Jolanta Pupure 1 Sergejs Isajevs Elina Skapare Juris Rumaks Simons Svirskis Darja Svirina Ivars Kalvinsh Vija Klusa
Affiliations

Affiliation

  • 1 Department of Pharmacology, Faculty of Medicine, University of Latvia, 1A Sarlotes, LV-1001, Riga, Latvia. pupure@e-apollo.lv
Abstract

Mildronate, a representative of the aza-butyrobetaine class of drugs with proven cardioprotective efficacy, was recently found to prevent dysfunction of complex I in rat liver mitochondria. The present study demonstrates that mildronate also acts as a neuroprotective agent. In a mouse model of azidothymidine (anti-HIV drug) neurotoxicity, mildronate reduced the azidothymidine-induced alterations in mouse brain tissue: it normalized the increase in Caspase-3, cellular Apoptosis susceptibility protein (CAS) and iNOS expression assessed by quantitative and semi-quantitative analysis. Mildronate also normalized the changes in cytochrome c oxidase (COX) expression, reduced the expression of glial fibrillary acidic protein (GFAP) and cellular infiltration. The present results show that the neuroprotective action of mildronate results at least partially from anti-neurodegenerative (anti-apoptotic) and anti-inflammatory mechanisms. It might be suggested that the molecular conformation of mildronate can facilitate its easy binding to mitochondria, and regulate the expression of different signal molecules, hence maintaining cellular signaling and survival.

Figures
Products